TCGA-55-8505-01A-11R-2403-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 62
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.520
- ANGIOGENESIS+0.380
- GLYCOLYSIS+0.370
- COAGULATION+0.360
- CHOLESTEROL_HOMEOSTASIS+0.340
- XENOBIOTIC_METABOLISM+0.340
- ADIPOGENESIS+0.300
- ESTROGEN_RESPONSE_EARLY+0.300
- HYPOXIA+0.280
- PANCREAS_BETA_CELLS+0.270
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.460
- E2F_TARGETS-0.450
- MYC_TARGETS_V1-0.440
- INTERFERON_GAMMA_RESPONSE-0.420
- INTERFERON_ALPHA_RESPONSE-0.400
- DNA_REPAIR-0.340
- G2M_CHECKPOINT-0.330
- MYC_TARGETS_V2-0.310
- IL2_STAT5_SIGNALING-0.120
- INFLAMMATORY_RESPONSE-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20060030.TNBC | — | F | 0.853 |
| 2 | SRR8613707 | — | C | 0.845 |
| 3 | TCGA-FD-A3SM-01A-11R-A22U-07 | — | — | 0.832 |
| 4 | TCGA-A2-A04W-01A-31R-A115-07 | — | C | 0.825 |
| 5 | SRR8518340 | — | F | 0.821 |
| 6 | TCGA-CV-7177-01A-11R-2016-07 | — | — | 0.818 |
| 7 | 20050118.TNBC | — | F | 0.814 |
| 8 | SRR8613710 | — | F | 0.810 |
| 9 | SRR8518146 | — | F | 0.807 |
| 10 | TCGA-OL-A5D6-01A-21R-A27Q-07 | — | F | 0.804 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.520 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.380 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.370 | Inavolisib | — uncovered |
| COAGULATION | 0.360 | Binimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.340 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.340 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.270 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.150 | Inavolisib | — uncovered |